Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulka Vaishampayan

Showing results (81-90 of 176) with videos related to

Pageof 18
Sort By:
Nutrition and Cancer|October 12, 2007
Lycopene and soy isoflavones in the treatment of prostate cancerUlka Vaishampayan, Maha Hussain, Mousumi Banerjee, et al.
Investigational New Drugs|September 3, 2024
Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancerElisabeth I Heath, Wei Chen, Lance Heilbrun, et al.
Cancer Chemotherapy and Pharmacology|April 13, 2007
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancerBassel F El-Rayes, Mark M Zalupski, Stephanie G Manza, et al.
Cancer|October 2, 2020
Discrepancies between genitourinary cancer patients' and clinicians' characterization of the Eastern Cooperative Oncology Group performance statusCristiane Decat Bergerot, Errol J Philip, Paulo Gustavo Bergerot, et al.
Journal for Immunotherapy of Cancer|October 26, 2019
Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trialUlka Vaishampayan, Patrick Schöffski, Alain Ravaud, et al.
European Journal of Cancer (Oxford, England : 1990)|April 13, 2011
Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinomaCamillo Porta, Susanne Osanto, Alain Ravaud, et al.
Cancer|June 10, 2011
Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapyDaniel Y C Heng, Wanling Xie, Georg A Bjarnason, et al.
JCO Precision Oncology|June 6, 2025
Validation of a 15-Gene Prognostic Signature in Metastatic Clear Cell Renal Cell CarcinomaSteven M Monda, Srinivas Nallandhighal, Ulka Vaishampayan, et al.
The American Journal of Pathology|March 29, 2005
Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissueZhong Dong, R Daniel Bonfil, Sreenivasa Chinni, et al.
Cancers|December 9, 2023
Analysis of the Tumor Immune Microenvironment (TIME) in Clear Cell Renal Cell Carcinoma (ccRCC) Reveals an M0 Macrophage-Enriched Subtype: An Exploration of Prognostic and Biological Characteristics of This Immune PhenotypeMark Farha, Srinivas Nallandhighal, Randy Vince, et al.
Pageof 18

Showing results (81-90 of 176) with videos related to

Sort By:
Pageof 18
Nutrition and Cancer|October 12, 2007
Lycopene and soy isoflavones in the treatment of prostate cancerUlka Vaishampayan, Maha Hussain, Mousumi Banerjee, et al.
Investigational New Drugs|September 3, 2024
Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancerElisabeth I Heath, Wei Chen, Lance Heilbrun, et al.
Cancer Chemotherapy and Pharmacology|April 13, 2007
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancerBassel F El-Rayes, Mark M Zalupski, Stephanie G Manza, et al.
Cancer|October 2, 2020
Discrepancies between genitourinary cancer patients' and clinicians' characterization of the Eastern Cooperative Oncology Group performance statusCristiane Decat Bergerot, Errol J Philip, Paulo Gustavo Bergerot, et al.
Journal for Immunotherapy of Cancer|October 26, 2019
Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trialUlka Vaishampayan, Patrick Schöffski, Alain Ravaud, et al.
European Journal of Cancer (Oxford, England : 1990)|April 13, 2011
Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinomaCamillo Porta, Susanne Osanto, Alain Ravaud, et al.
Cancer|June 10, 2011
Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapyDaniel Y C Heng, Wanling Xie, Georg A Bjarnason, et al.
JCO Precision Oncology|June 6, 2025
Validation of a 15-Gene Prognostic Signature in Metastatic Clear Cell Renal Cell CarcinomaSteven M Monda, Srinivas Nallandhighal, Ulka Vaishampayan, et al.
The American Journal of Pathology|March 29, 2005
Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissueZhong Dong, R Daniel Bonfil, Sreenivasa Chinni, et al.
Cancers|December 9, 2023
Analysis of the Tumor Immune Microenvironment (TIME) in Clear Cell Renal Cell Carcinoma (ccRCC) Reveals an M0 Macrophage-Enriched Subtype: An Exploration of Prognostic and Biological Characteristics of This Immune PhenotypeMark Farha, Srinivas Nallandhighal, Randy Vince, et al.
Pageof 18